pharma · Hemophilia · Gaucher's disease type I; Gaucher's disease type III
Genzyme Europe
Genzyme Europe B.V.
Genzyme Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hemophilia, Gaucher's disease type I; Gaucher's disease type III, Primary Progressive Multiple Sclerosis, Hemophilia A
NL HQ
1981 Founded
273 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- NL
- Founded
- 1981
- Employees
- 273
- Programs
- 5
- Drugs
- 10
- Patents
- 0
EFC16035
Phase 3 · small molecule · Primary Progressive Multiple Sclerosis
EFC16035 for Primary Progressive Multiple Sclerosis is a Phase 3 program (small_molecule) at Genzyme Europe B.V. with 1 ClinicalTrials.gov record(s).
Internal code EFC16035
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Genzyme Europe B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Primary Progressive Multiple Sclerosis
- Status
- active
- Trials
- 1